CPRX News and Press, Catalyst Pharmaceuticals Inc. From 06/04/22

It's no secret that investors flock to biotech stocks for exposure to moonshot returns. For instance, if you invested in Catalyst Pharmaceuticals (NASDAQ: CPRX) around five years ago, you are sitting with a gain of about 239% compared to the market's total return of near 87%. Th...

BofA Securities screened for stocks with the the characteristics most likely to attract suitors, both in the large- and small-cap universes. For S&P 500 (SP500) (SPY) targets, BofA: Screens based on its preferred valuation metric of free cash flow to enterprise value (FCF/EV) for those tr...

Catalyst Pharmaceuticals (NASDAQ:CPRX) Q1 non-GAAP EPS grew +63.64% Y/Y to $0.18 and the company reaffirmed its FY22 revenue outlook. Total revenues rose +42.66% to $43.03M Y/Y. The company said the increase reflected steady growth for its drug Firdapse, to treat pediatric patients with ...

Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Ali Grande - Vice President, Chief Financial Officer and Treasurer Patrick McEnany - Chairman and Chief Executive Officer Jeff Del Carmen - Chief Commercial Officer Steven Mille...

Catalyst has outperformed during 2022 despite a brutal biotech market. Catalyst minds its knitting and does well by doing so. Catalyst reported strong earnings for Q1 2022. For further details see: Catalyst: Upside Outlier - In Search Of A Catalyst

Catalyst Pharmaceuticals press release (NASDAQ:CPRX): Q1 Non-GAAP EPS of $0.18. Revenue of $43.09M (+42.6% Y/Y). Shares +1.6%. Guidance: The Company continues to forecast full year 2022 total revenues to be in the range of between $195 million and $205 million, representing a 38% - 45% i...

Achieved Record Revenues of more than $43 Million, a 42.7% Increase YoY Three New Patents Issued; Now Five Orange-Book Listed Patents for FIRDAPSE ® Significant Cash Position of $198 Million and No Funded Debt Advanced Plans to Diversify and Invest in In...

CORAL GABLES, Fla., April 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announc...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Arcos Dorados ( ARCO ): A fast food franchisee serving Latin America. Catalyst Pharmaceuticals ( CPRX ): This biopharmaceutical firm focuses on rare debilitating neuromuscular and neurodegenerative diseases. ...

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) traded today at a new 52-week high of $8.41. So far today approximately 301,000 shares have been exchanged, as compared to an average 30-day volume of 1.3 million shares. Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) defies analysts with a curren...